Osteopontin/OPN Antibody - BSA Free

Western Blot: Osteopontin/OPN Antibody - BSA Free [NBP1-59190] -

Western blot analysis of principal marker of bone homing. (A) Western blot analysis of Versican, Osteopontin, and Prolactin receptor in MCF-7 cells untreated and treated with IL-1 beta and AZA after 48 h. Representative images of WB and densitometric analysis (Mean +/- SD) of Versican, Osteopontin, and Prolactin receptor. One-way ANOVA showed significant effect of treatment on densitometric data (p < 0.0005); significant differences were highlighted among tested treatments (p < 0.0005), except for Prolactin receptor with AZA (NS). (B) Western blot analysis of Versican, Osteopontin, and Prolactin receptor in MCF-7 cells untreated and treated with IL-1 beta and Bobcat339 (33 uM and 75 uM) and relative co-treatments after 48 h. Representative images of WB and densitometric analysis (Mean +/- SD, n = 3) of Versican, Osteopontin, and Prolactin receptor. One-way ANOVA showed significant effect of treatment on densitometric data; significant differences among tested treatments versus untreated MCF-7 (*), and among IL-1 beta /BC co-treatments versus the IL-1 beta one () are reported in the graphs (*** and, p < 0.0005). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36499741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Osteopontin/OPN Antibody - BSA Free [NBP1-59190] -

Western blot analysis of principal marker of bone homing. (A) Western blot analysis of Versican, Osteopontin, and Prolactin receptor in MCF-7 cells untreated and treated with IL-1 beta and AZA after 48 h. Representative images of WB and densitometric analysis (Mean +/- SD) of Versican, Osteopontin, and Prolactin receptor. One-way ANOVA showed significant effect of treatment on densitometric data (p < 0.0005); significant differences were highlighted among tested treatments (p < 0.0005), except for Prolactin receptor with AZA (NS). (B) Western blot analysis of Versican, Osteopontin, and Prolactin receptor in MCF-7 cells untreated and treated with IL-1 beta and Bobcat339 (33 uM and 75 uM) and relative co-treatments after 48 h. Representative images of WB and densitometric analysis (Mean +/- SD, n = 3) of Versican, Osteopontin, and Prolactin receptor. One-way ANOVA showed significant effect of treatment on densitometric data; significant differences among tested treatments versus untreated MCF-7 (*), and among IL-1 beta /BC co-treatments versus the IL-1 beta one () are reported in the graphs (*** and, p < 0.0005). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36499741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.